Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101
Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the…
